half-life is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-29. Numbers and descriptions here follow the published literature rather than marketing material.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
== Interaction with other civilisations == The Culture, living mostly on massive spaceships and in artificial habitats, and also feeling no need for conquest in the typical sense of the word, possesses no borders. Its sphere of influence is better defined by the (current) concentration of Culture ships and habitats as well as the measure of effect its example and its interventions have already had on the "local" population of any galactic sector. As the Culture is also a very graduated and constantly evolving society, its societal boundaries are also constantly in flux (though they tend to be continually expanding during the novels), peacefully "absorbing" societies and individuals. While the Culture is one of the most advanced and most powerful of all galactic civilisations, it is still but one of the "high-level Involved" (called "Optimae" by some less advanced civilisations), the most powerful non-sublimed civilisations which mentor or control the others. An Involved society is a highly advanced group that has achieved galaxy-wide involvement with other cultures or societies. There are a few dozen Involved societies and hundreds or thousands of well-developed (interstellar) but insufficiently influential societies or cultures. The well-developed societies which do not take a dynamic role in the galaxy as a whole are designated as "galactically mature". In the novels, the Culture might be considered the premier Involved society, or at least the most dynamic and energetic, especially given that the Culture itself is a growing multicultural fusion of Involved societies.
Anti-inflammatory: Calotropis extracts have been used traditionally to alleviate inflammation. The latex of the plant contains compounds that possess anti-inflammatory properties. Traditional uses of Calotropis include treating skin conditions such as eczema, psoriasis, and other inflammatory skin disorders. Its anti-inflammatory and wound-healing properties may contribute to these potential benefits. Antimicrobial: Certain parts of Calotropis, especially the latex, have shown antimicrobial activity against various bacterial and fungal pathogens. This property has been utilized in traditional medicine to treat skin infections and wounds. The antimicrobial activity of Calotropis plants has been attributed to the presence of various bioactive compounds such as alkaloids, flavonoids, and terpenoids. A study found that the latex of Calotropis procera has significant antimicrobial activity against various bacterial and fungal pathogens, including Staphylococcus aureus, Escherichia coli, and Candida albicans Wound Healing: The latex of Calotropis has been used topically to promote wound healing. It is believed to help in the formation of granulation tissue and facilitate the healing process. Analgesic (Pain Relief): Some traditional practices involve using Calotropis preparations to relieve pain and discomfort. Gastrointestinal Disorders: Some traditional medicinal practices use Calotropis to alleviate gastrointestinal issues such as constipation and dysentery. However, its laxative effects are strong and can lead to adverse effects.
For instance, Tito's regime neither crushed Croatia's Catholic and Serbia's Orthodox identities into East German-style irrelevance, nor left either intact enough to serve, Solidarity-fashion, as a vehicle for negotiated transition. Instead, it suppressed several rival national-religious identities simultaneously without reconciling or replacing any of them, executing their clergy while never granting any single church the institutional standing that might have channeled opposition into round-table bargaining rather than open war. When Yugoslav communism finally exhausted itself, there was accordingly no Solidarity and no East German round table to absorb the shock—only the unmediated return of grievances a generation of enforced silence had left to fester rather than resolve. This reading of Yugoslavia as suppression without resolution sits within a wider historiographical debate over causes, since the disintegration of Yugoslavia was, in historian Konrad Jarausch's opinion, the most drastic result of a failed post-communist transition anywhere in the former bloc. Jarausch stresses that some scholars point to "ancient hatreds" rooted in Ottoman rule or wartime collaboration, others to nationalism's revival as a substitute ideology across the whole post-communist world, still others to outside interference—chiefly the German-led recognition of Slovenian and Croatian independence—or to failed Western mediation.
During his second presidency, Donald Trump launched a campaign of anti-LGBTQ+ and especially anti-transgender policies that eliminated federal recognition of transgender people, stripped legal protections, and sought to erase trans identities from public life. Through a series of executive orders, the administration defined sex strictly by birth biology, banned trans people from the military, restricted or defunded gender-affirming healthcare, censored research and education materials, and targeted schools, universities, and cultural institutions accused of promoting "gender ideology". Additional measures barred transgender athletes from sports, limited passport access, and fueled international efforts to undermine trans rights. Accompanied by rhetoric portraying transgender people as a societal threat, these policies triggered widespread legal challenges, condemnation from human rights groups, and a surge in emigration and asylum claims by transgender Americans.
==== GSK–Pfizer joint venture ==== In December 2018, GSK announced that it, along with Pfizer, had reached an agreement to merge and combine their consumer healthcare divisions into a single entity. The combined entity would have sales of around £9.8 billion ($12.7 billion), with GSK maintaining a 68% controlling stake in the joint venture. Pfizer would own the remaining 32% shareholding. The deal builds on an earlier 2018 deal where GSK bought out Novartis' stake in the GSK-Novartis consumer healthcare joint business.
Sources: en.wikipedia.org
== Discovery == The parent structure of lefetamine, 1,2-diphenylethylamine was first synthesized in the 1940s and showed weak analgesic activity. Lefetamine itself was first investigated in Japan in the 1950s. The L-isomer showed weak analgesic action comparable to codeine and antitussive action far weaker than codeine. The d-isomer showed no such activity but caused seizures in rats.
While high oral doses of selegiline (≥20 mg/day) can cause such interactions, oral doses within the approved clinical range (≤10 mg/day) appear to have little to no risk of these interactions. In addition, the ODT and transdermal forms of selegiline have reduced risks of such interactions compared to the conventional oral form. Selegiline is also contraindicated in children less than 12 years of age and in people with pheochromocytoma, both due to heightened risk of hypertensive crisis. For all human uses and all forms, selegiline is pregnancy category C, meaning that studies in pregnant animals have shown adverse effects on the fetus but there are no adequate studies in humans.
3 April – NASA selects three companies – Intuitive Machines, Lunar Outpost and Venturi Astrolab – to develop its Lunar Terrain Vehicle, for use in crewed Artemis missions from 2030 onwards. 4 April A study in Nature finds that global CO2 emissions increased by only 0.1% in 2023, suggesting that a plateau may have been reached. The Dark Energy Spectroscopic Instrument (DESI) project releases multiple papers which report unprecedented measurements of dark energy, find indications that dark energy which is expanding the Universe is evolving over time, and release the most detailed largest 3D cosmic map to date. 5 April – A numerical toolkit designed for modelling warp drive spacetimes is introduced in Classical and Quantum Gravity. 9 April – A rare genetic variation in a gene that makes fibronectin is shown to reduce the odds of developing Alzheimer's disease by over 70%. 11 April – The first nitrogen-fixing organelle in a marine alga is reported, the nitroplast. The early evolutionary stage organelle provides a view into the transition from an endosymbiont into a proper organelle that receives about half of its proteins from the alga. 12 April Biologists report that bonobos behave more aggressively than thought earlier. Scientists describe how tardigrades are protecting themselves from large radiation exposure and damage, which is quickly repaired, using the Dsup protein. 15 April The NOAA confirms a fourth global coral bleaching event. The world's first commercial-scale factory producing sustainable high-protein food from air, microbes and solar energy, Solein, launches.
Going back more than 350 years, the first landmark description was of general blood circulation by William Harvey in 1628, which formed the anatomical basis for intravenous infusions. Investigations during the following centuries demonstrated solutions containing electrolytes and glucose could be given intravenously. The accumulated knowledge of protein metabolism formed the basis for studies on intravenous nutrition with protein hydrolysates, peptides, and amino acids. Robert Elman's observation in the late 1930s that amino acids in the form of protein hydrolysate could be administered safely was the first major step toward TPN. During the following years, major efforts were made to find methods to prepare infusion solutions with a high energy content and low osmotic pressure. The most realistic alternative seemed to be fat in the form of an emulsion. Many studies of a large number of various fat emulsions were made from the 1920s until the end of the 1950s. However, all of these emulsions caused severe adverse reactions. The first safe fat emulsion, Intralipid, developed by Prof. Arvid Wretlind of the Karolinska Institute, Sweden, was made available for clinical use in 1962. This was the second major step toward TPN. Vitamins, electrolytes, and trace elements were then included in the fat emulsions and in the solutions of amino acids and glucose. Later in the 1960s, Dr. Stanley Dudrick, who as a surgical resident in the University of Pennsylvania, working in the basic science laboratory of Dr.
Sources: en.wikipedia.org
The lawsuit continued to the Supreme Court after Schmitt left the office of attorney general. In Biden v. Nebraska, the Court held that the United States Secretary of Education lacked the authority to waive student loans.
). The question raised but not answered by this study was whether the illness caused subtle immune deficiency that led to reactivation of HHV-6, or whether reactivation of HHV-6 led to the symptoms of the illness. Subsequent studies employing only serological techniques that do not distinguish active from latent infection have produced mixed results: most, but not all, have found an association between CFS and HHV-6 infection. Other studies have employed assays that can detect active infection: primary cell culture, PCR of serum or plasma, or IgM early antigen antibody assays. The majority of these studies have shown an association between CFS and active HHV-6 infection, although a few have not. In summary, active infection with HHV-6 is present in a substantial fraction of patients with CFS. Moreover, HHV-6 is known to infect cells of the nervous system and immune system, organ systems with demonstrable abnormalities in CFS. Despite this association, it remains unproven that reactivated HHV-6 infection is a cause of CFS.
==== 2016: Redshirt season ==== Following his matriculation at the University of Oregon in the spring of 2016, McCormick redshirted his freshman season while recovering from his knee injury. By August 2016, McCormick had been cleared to fully participate in football activities, though he was required to wear a knee brace. In September 2016, McCormick told The Oregonian that the brace may be blunting his speed, owing to the brace's impact on his natural running motion.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.